摘要 |
There is provided a CRF receptor antagonist comprising a compound of the formula (I) : A-W-Ar wherein, A is a group represented by the formula (A2), wherein ring Ab is a 5- or 6- membered ring which may be further substituted in addition to R1; ring Ac is a 5- or 6- membered ring which may be substituted; R1 is an optionally substituted hydrocarbyl, a substituted amino, an optionally substituted cyclic amino, a substituted hydroxy, a substituted sulfanyl, an optionally substituted sulfinyl, or an optionally substituted sulfonyl;
X is carbonyl, -O-, -S-, -SO-, or -SO2-; Y1, Y2 and Q are independently optionally substituted carbon or nitrogen; ... is a single or double bond; W is a bond, an optionally substituted methylene, an optionally substituted ethylene, an optionally substituted imino, -O-, -S-, -SO-, or -SO2-; Ar is an optionally substituted aryl or an optionally substituted heteroaryl; or a salt thereof or a prodrug thereof.
|
申请人 |
TAKEDA PHARMACEUTICAL COMPANY LIMITED |
发明人 |
GYORKOS, ALBERT CHARLES;BOYD, S. A.;CORRETTE, C. P.;CHO, S. Y.;TURNER, T. M.;ASO, K.;KORI, M.;MOCHIZUKI, M.;CONDROSKI, K. R.;SIEDEM, C. S. |